Fulcrum Therapeutics Inc. and Slate Medicines Inc. have agreed to merge in an all-stock transaction valued at approximately $245 million, the companies said on Monday.
Under the terms of the deal, Fulcrum shareholders will receive shares of the combined company, which will operate under the Fulcrum name and focus on gene therapy development. The merger aims to combine Fulcrum’s pipeline of muscular dystrophy treatments with Slate’s gene therapy platform, creating a broader portfolio of therapies for rare diseases.
The transaction is expected to close in the second half of 2025, subject to customary regulatory approvals and shareholder votes. Fulcrum will retain its Nasdaq listing under the ticker FULC, while Slate Medicines will dissolve as a standalone entity. Financial terms include an exchange ratio of 0.42 Fulcrum shares for each Slate share, based on the companies’ closing prices on May 17, 2025.
Management of the combined company will be led by Fulcrum’s current leadership team, with Slate’s CEO joining the board. The merger is structured to minimize dilution for Fulcrum shareholders while providing Slate with capital to advance its pipeline. Both companies cited synergies in research and development as key drivers of the deal.
Analysts view the merger as a strategic move to strengthen Fulcrum’s position in the competitive gene therapy market, where consolidation has accelerated in recent years. The combined entity will have a combined market capitalization of roughly $500 million post-merger, based on current Fulcrum share prices.
